VEGFR
VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.
Products for VEGFR
- Cat.No. Product Name Information
-
GC13944
(5Z)-7-Oxozeaenol
FR148083,L-783,279,LL-Z 1640-2
TAK1 mitogen-activated protein kinase kinase kinase (MAPKKK) inhibitor
- GC17800 (E)-FeCP-oxindole VEGFR-2 inhibitor
- GC13344 (Z)-FeCP-oxindole VEGFR-2 inhibitor
-
GC62291
(Z)-Orantinib
(Z)-SU6668; (Z)-TSU-68
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. -
GC33087
2,4-Pyrimidinediamine with linker
VEGFR-2-IN-5
2,4-Pyrimidinediamine with linker is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69. - GC25017 4,4'-Bis(4-aminophenoxy)biphenyl 4,4'-Bis(4-aminophenoxy)biphenyl is a monomer for polyimide production.
- GC63805 4SC-203 4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs.
-
GC68568
5α-Hydroxycostic acid
5α-Hydroxycostic acid is a diterpenoid extracted from the herb Laggera alata. It inhibits angiogenesis and suppresses breast cancer cell migration by regulating the VEGF/VEGFR2 and Ang2/Tie2 pathways.
-
GC10938
AAL-993
VEGFR Tyrosine Kinase Inhibitor VI,ZK 260253
VEGF receptors inhibitor -
GC30242
Acrizanib
LHA510
Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2. -
GC15801
ACTB-1003
ACTB-1003
ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. -
GC68628
Aflibercept
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
Aflibercept (VEGF Trap) is a soluble decoy VEGFR composed of Ig domains from VEGFR1 and VEGFR2 fused to the Fc domain of human IgG1. Aflibercept inhibits the VEGF signaling pathway by blocking pathways regulated by VEGF. Aflibercept can be used in research for age-related macular degeneration (AMD) and cardiovascular diseases.
- GC35263 AG-13958 AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD).
-
GC16604
Altiratinib
DCC-2701
c-MET/TIE-2/VEGFR inhibitor -
GC14292
Apatinib Mesylate
YN968D1
Apatinib blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.
-
GC10914
AST 487
NVP-AST 487
A multi-kinase inhibitor -
GC12216
Axitinib (AG 013736)
AG 013736
Axitinib (AG 013736) is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. -
GC62185
Axitinib-d3
AG-013736-d3
Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. - GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit
-
GC11726
BAW2881 (NVP-BAW2881)
NVP-BAW 2881
BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM. - GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab (Anti-Human VEGF, Humanized Antibody), a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
- GC15340 BFH772 VEGFR2 inhibitor
- GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.
- GC50330 BMS 605541 Potent VEGFR-2 inhibitor
- GC13873 BMS-690514
- GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive
-
GC11692
Brivanib (BMS-540215)
BMS 540215
Brivanib (BMS-540215) (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. -
GC14238
Brivanib Alaninate (BMS-582664)
BMS 582664
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ. -
GC15779
Cabozantinib (XL184, BMS-907351)
BMS-907351, Cabozantinib
Cabozantinib (XL184, BMS-907351) is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib (XL184, BMS-907351) displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib (XL184, BMS-907351) shows antiangiogenic activity. Cabozantinib (XL184, BMS-907351) disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis. - GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
GC67948
Cabozantinib-d6
XL184-d6; BMS-907351-d6
-
GC16421
Cediranib (AZD217)
AZD 2171, ZD 2171
Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. - GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
- GC14650 CGP60474 A CDK inhibitor
-
GC62145
Chiauranib
CS2164
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. - GC32979 Chloropyramine hydrochloride Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.
- GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF
- GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy.
- GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.
- GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective
- GC17098 DMH4 VEGFR-2 inhibitor
- GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
- GC11372 Dovitinib Dilactic acid FLT3 inhibitor
- GC12149 E-3810
-
GC16183
EG00229
Nrp1 inhibitor
- GC16519 ENMD-2076 A multi-kinase inhibitor
- GC12145 ENMD-2076 L-(+)-Tartaric acid
- GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis.
- GC72336 Faricimab Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A).
-
GC15735
Foretinib (GSK1363089)
GSK1363089, XL880
Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. -
GC10355
Fruquintinib(HMPL-013)
HMPL-013
Fruquintinib(HMPL-013) (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively. -
GC17715
Golvatinib (E7050)
E7050
Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. - GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM.
- GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
- GC32963 hVEGF-IN-1 hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression.
-
GC43885
Hypothemycin
NSC 354462
A resorcylic acid lactone polyketide -
GC69252
Icrucumab
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized monoclonal antibody against VEGFR-1 IgG1. Icrucumab has the potential for use in late-stage solid tumor research.
-
GC34159
Ilorasertib (ABT-348)
ABT-348
Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). -
GC38519
Ilorasertib hydrochloride
ABT-348 hydrochloride
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). -
GC18168
JI-101
CGI1842
An orally active inhibitor
-
GC32625
KDR-in-4
KDR-in-4
KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. -
GC13264
Ki20227
Ki 20227;Ki-20227
A c-Fms kinase inhibitor - GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective
- GC12590 KRN 633 VEGFR inhibitor,ATP-competitive
-
GC15454
Lenvatinib (E7080)
E-7080, ER-203492-00
Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. -
GC36438
Lenvatinib mesylate
E-7080
An inhibitor of VEGFR2 and VEGFR3 -
GC17958
Linifanib (ABT-869)
Linifanib
Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. -
GC13848
LY2784544
Gandotinib
Potent inhibitor of JAK2 - GC16483 MAZ51 VEGFR3 antagonist
- GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity.
- GC13012 Motesanib
-
GC11336
Motesanib Diphosphate (AMG-706)
Motesanib
Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. - GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib
- GC18211 Ningetinib A multi-kinase inhibitor
- GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
-
GC36745
Nintedanib esylate
Nintedanib
Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). - GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
- GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment.
- GC32502 Oglufanide (H-Glu-Trp-OH) Oglufanide (H-Glu-Trp-OH) (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus.
- GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck
-
GC69662
Parsatuzumab
Anti-EGFL7; RG 7414
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody that binds to EGFL7 as an immune modulator. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, which may inhibit angiogenesis and reduce the inhibition of vascular endothelial growth factor (VEGF).
-
GC16327
Pazopanib (GW-786034)
GSK-VEG10003, GW786034B
A multi-kinase inhibitor -
GC12730
Pazopanib Hydrochloride
GW786034;Votrient;Armala;GW 786034;GW-786034
VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor -
GC64346
Pegaptanib sodium
EYE001; NX1838
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. -
GC60283
Pentagamavunon-1
PGV-1
Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation. - GC18074 PF-03814735 PF-03814735 is a potent, orally bioavailable, reversible inhibitor of both Aurora1 and Aurora2 kinases with IC50 values of 0.8nM and 5nM, respectively [1].
-
GC14396
Ponatinib (AP24534)
AP 24534
Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. - GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib
- GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases
-
GC65335
PTC299
PTC-299
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies. - GC37047 Pz-1 Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases.
- GC12857 R1530 A multi-kinase inhibitor
- GC33271 R916562 R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.
-
GC15818
RAF265
CHIR-265;RAF 265;RAF-265;CHIR265
Multiple intracellular kinases inhibitor -
GC19534
Ramucirumab
LY3009806
Ramucirumab is a fully human monoclonal antibody (IgG1).
- GC14606 Regorafenib hydrochloride A multi-kinase inhibitor
- GC14534 Regorafenib monohydrate A multi-kinase inhibitor
-
GC64895
Regorafenib-d3
BAY 73-4506-d3
Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor. -
GC37538
Ripretinib
DCC-2618
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. -
GC12586
SAR131675
VEGFR3 inhibitor,selective and ATP-competitve